Publications by authors named "R Chaligne"

Single-cell genomics technologies have accelerated our understanding of cell-state heterogeneity in diverse contexts. Although single-cell RNA sequencing identifies rare populations that express specific marker transcript combinations, traditional flow sorting requires cell surface markers with high-fidelity antibodies, limiting our ability to interrogate these populations. In addition, many single-cell studies require the isolation of nuclei from tissue, eliminating the ability to enrich learned rare cell states based on extranuclear protein markers.

View Article and Find Full Text PDF

Ageing is associated with a decline in the number and fitness of adult stem cells. Ageing-associated loss of stemness is posited to suppress tumorigenesis, but this hypothesis has not been tested in vivo. Here we use physiologically aged autochthonous genetically engineered mouse models and primary cells to demonstrate that ageing suppresses lung cancer initiation and progression by degrading the stemness of the alveolar cell of origin.

View Article and Find Full Text PDF

As cancers progress, they become increasingly aggressive-metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death. Mutations are largely conserved between primary and metastatic tumours from the same patients, suggesting that non-genetic phenotypic plasticity has a major role in cancer progression and therapy resistance. However, we lack an understanding of metastatic cell states and the mechanisms by which they transition.

View Article and Find Full Text PDF
Article Synopsis
  • * The study reveals that RAS mutations transform specific blood cell progenitors (granulocyte-monocyte progenitors) that have already acquired other mutations, suggesting advanced leukemia can arise from different cell types than initial clones.
  • * RAS-mutant leukemia stem cells show resistance to the treatment drug venetoclax due to changes in gene expression, leading to worse treatment responses and relapses characterized by monocytic features, highlighting the impact of genetic drivers on therapy effectiveness.
View Article and Find Full Text PDF